Crinetics Pharmaceuticals, Inc. (CRNX)

NASDAQ: CRNX · IEX Real-Time Price · USD

45.54

-0.53 (-1.15%)

At close: Jul 2, 2024, 4:00 PM

45.24

-0.30 (-0.66%)

After-hours: Jul 2, 2024, 4:31 PM EDT

Crinetics Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2016
Revenue	4.01	4.74	1.08	0.07	1.19	Upgrade
Revenue Growth (YoY)	-15.28%	339.42%	1418.31%	-94.05%	-50.86%	Upgrade
Gross Profit	4.01	4.74	1.08	0.07	1.19	Upgrade
Selling, General & Admin	58.09	42.39	24.53	18.03	13.52	Upgrade
Research & Development	168.53	130.23	84.26	57	41.51	Upgrade
Operating Expenses	226.62	172.62	108.78	75.02	55.03	Upgrade
Operating Income	-222.61	-167.88	-107.7	-74.95	-53.83	Upgrade
Other Expense / Income	-8.08	-3.96	-0.06	-1.14	-3.41	Upgrade
Pretax Income	-214.53	-163.92	-107.64	-73.81	-50.42	Upgrade
Net Income	-214.53	-163.92	-107.64	-73.81	-50.42	Upgrade
Shares Outstanding (Basic)	58	52	38	30	24	Upgrade
Shares Outstanding (Diluted)	58	52	38	30	24	Upgrade
Shares Change	11.71%	35.24%	26.23%	25.95%	99.10%	Upgrade
EPS (Basic)	-3.69	-3.15	-2.80	-2.42	-2.09	Upgrade
EPS (Diluted)	-3.69	-3.15	-2.80	-2.42	-2.09	Upgrade
Free Cash Flow	-171	-116.86	-89.02	-62.21	-46.87	Upgrade
Free Cash Flow Per Share	-2.94	-2.25	-2.32	-2.04	-1.94	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-5547.17%	-3544.06%	-9990.91%	-105567.61%	-4512.32%	Upgrade
Profit Margin	-5345.85%	-3460.38%	-9985.25%	-103960.56%	-4226.49%	Upgrade
Free Cash Flow Margin	-4261.03%	-2466.98%	-8258.26%	-87623.94%	-3929.00%	Upgrade
EBITDA	-212.22	-162.53	-106.38	-72.59	-49.31	Upgrade
EBITDA Margin	-5288.34%	-3431.05%	-9868.18%	-102233.80%	-4133.19%	Upgrade
Depreciation & Amortization	2.31	1.39	1.26	1.23	1.11	Upgrade
EBIT	-214.53	-163.92	-107.64	-73.81	-50.42	Upgrade
EBIT Margin	-5345.85%	-3460.38%	-9985.25%	-103960.56%	-4226.49%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).